Neurophet names Lawrence Tanenbaum scientific advisor

Neurophet has appointed neuroradiologist Lawrence N. Tanenbaum, MD, FACR, as scientific advisor. The company said the appointment is intended to support clinical validation, global expansion, and neuroimaging AI competitiveness.

Tanenbaum has more than 30 years of experience across clinical practice, academic research, healthcare technology, and imaging AI. He most recently served as vice president and chief technology officer at RadNet, where he led imaging technology strategy and AI integration across the company’s national imaging network, according to Neurophet.

Before RadNet, Tanenbaum was director of MRI, CT, and advanced imaging and associate professor of radiology at the Icahn School of Medicine at Mount Sinai in New York. He is also a fellow of the American College of Radiology and has served on the Roster of Distinguished Scientific Advisors of RSNA.

Neurophet said Tanenbaum has held advisory and leadership roles at more than 20 AI and imaging companies. The company plans to use his clinical and industry network, particularly in the U.S., to expand collaborations with healthcare institutions and industry partners.

“Neurophet possesses an impressive combination of technological innovation and strategic vision,” Tanenbaum said. He added that he plans to contribute to AI-powered imaging technologies with clinical value in real-world practice.

Neurophet’s portfolio includes Neurophet AQUA for brain MRI analysis, Neurophet SCALE PET for PET image quantitative analysis, Neurophet tES/TMS LAB for brain stimulation planning, Neurophet AQUA AD for Alzheimer’s disease treatment monitoring, and Neurophet AQUA MS for multiple sclerosis image analysis.

In February, Neurophet received U.S. Food and Drug Administration 510(k) clearance for Neurophet AQUA AD Plus. The company described the clearance as its 3rd U.S. regulatory milestone, following AQUA and SCALE PET.

“Dr. Tanenbaum is one of the world’s foremost experts at the intersection of medical imaging and artificial intelligence,” said Jake Junkil Been, co-CEO of Neurophet. Been said the appointment is expected to support the company’s clinical credibility and expansion in the U.S. and other global markets.